Prognostic significance of autoimmunity during treatment of melanoma with interferon.
about
Cancer vaccinesInterferon-α abrogates tolerance induction by human tolerogenic dendritic cellsIncreased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma.Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma.Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomasSafety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapyA phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.A new era in the treatment of melanoma: from biology to clinical practice.Adjuvant therapy for high-risk melanomaQ56898598
P2860
Q27024438-02EE8A09-570A-4CFC-9719-3C537E444B64Q33983425-3C38E433-D4AF-4B79-8E1C-DC78FC431B43Q34313600-FE2832BC-B6F5-4B4C-BD3D-2053B2EECE78Q34425709-D82FCAAE-3F4B-4EA0-9824-C72DC5BD5C3FQ35845352-D68FB87E-44AE-4853-96F0-7AC79E4FF367Q36174230-72B5692E-8F49-43C1-B159-9091581E80FEQ36353361-C886B22C-44A2-4A9A-B103-96C43CFA8677Q36443331-632576D2-B090-41CF-8B04-977B3A66C5A8Q36824656-1600678C-2C5A-4E42-8406-9317A56D9758Q37518314-77B2A2C3-1E96-4E92-8B53-5C25BA9E4322Q37956047-E056E128-CCA5-4D49-A810-7FF3D6103E5CQ38555842-6C797680-59D8-427B-8409-F221794EC0A3Q56898598-E28749C6-84ED-408F-BE2F-D568A24D472E
P2860
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
@en
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
@nl
type
label
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
@en
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
@nl
prefLabel
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
@en
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
@nl
P2093
P2860
P1476
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
@en
P2093
Ahmad Tarhini
Helen Gogas
John M Kirkwood
Michal T Krauze
P2860
P2888
P304
P356
10.1007/S00281-011-0247-Y
P577
2011-01-31T00:00:00Z